Pre-earnings options volume in Reviva Pharmaceuticals Holdings is normal with calls leading puts 2:1. Implied volatility suggests the market is anticipating a move near 10.5%, or 65c, after results are released. Median move over the past eight quarters is 15.2%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVPH:
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) Q3 Earnings Cheat Sheet
- Reviva Pharmaceuticals price target raised to $20 from $10 at H.C. Wainwright
- Reviva data robust across multiple endpoints, says Roth MKM
- Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
- Reviva Pharmaceuticals announces Phase 3 RECOVER trial met primary endpoint